Prabhudas Lilladher's research report on Bayer Cropscience
Bayer reported better than expected results with robust growth in both crop protection and seeds segment. Topline/EBITDA/APAT grew by 29%/61%/57% YoY. Gross margin contraction of 240 bps would have been largely due to higher sales growth of Roundup (Glyphosate) which is a low margin product for the company. Liquidation growth continues to be better than placement growth implying limited build-up of stocks at the dealer level. With robust paddy plantings and decent growth in Corn acreages, seeds segment is expected to sustain high growth. Lower labour availability, remunerative crop prices and well distributed monsoon will drive crop protection segment growth while leveraging synergy benefits from Monsanto acquisition will aid profits.
Outlook
We roll forward to Sept’22 earnings while marginally increasing our topline and EBITDA estimates for FY21 & FY22, maintain BUY rating with revised target price of Rs 6421 based on 35x Sep’22 earnings. Bayer remains our preferred pick in agchem space considering turnaround compelled by new management and robust free cashflow generation.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.